Pharmaceutical Companies Keep Biomarker and Diagnostic Development In-House, Finds Cutting Edge Information
08:23 EDT 6 Sep 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Developing companion diagnostics (CDx) is a time sensitive project and
the majority of drug companies prefer to keep at least some CDx
development in-house. According to new research by Cutting Edge
Information, 61% of surveyed ...
Other Sources for this Article
Cutting Edge Information
Elio Evangelista, 919-403-6583
More From BioPortfolio on "Pharmaceutical Companies Keep Biomarker and Diagnostic Development In-House, Finds Cutting Edge Information"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
